Navigation Links
Patients with PsA treated with ustekinumab are twice as likely to achieve acr20 vs. placebo

Berlin, Germany, June 8 2012: A new Phase III study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, shows that patients with active psoriatic arthritis (PsA) treated with Ustekinumab (UST) 90mg were more than twice as likely to achieve the study's primary endpoint, ACR20* at 24 weeks, than those treated with placebo (49.5% vs 22.8%). 42.4% of patients treated with UST 45mg were also more likely to achieve ACR20 at 24 weeks compared to placebo.

Significant improvements were also seen with UST 45mg and 90mg in ACR50* (24.9% and 27.9% respectively vs 8.7%), in ACR70* (12.2% and 14.2% respectively vs 2.4%) and in DAS28-CRP** responses at week 24 vs placebo (65.9% and 67.6% for UST 45mg and 90mg respectively vs 34.5%). Changes from baseline in HAQ-DI*** at week 24 were also significantly greater in patients treated with UST versus placebo and for a greater proportion of patients these changes were clinically meaningful (≥0.3).

In addition, patients in the UST groups who were affected with enthesitis (n=425) or dactylitis (n=286) at baseline, showed greater improvements at week 24 than those in the placebo groups.

"There are a number of patients with psoriatic arthritis who do not respond to currently available treatment options, including biologic medicines targeting TNF. As physicians, we struggle to manage such people as well as we would like," commented Professor Iain McInnes, lead study author from University of Glasgow, Scotland. "The development of this new medicine is a welcome step forward. These results highlight not only Ustekinumab's efficacy but also its promising safety profile. We look forward now to seeing how it compares in trials with standard treatments."

Safety profiles were similar between the two groups. The proportion of patients suffering from one or more adverse events was 41.8% in the UST group compared to 42% in the placebo group. Infections were the most common adverse event; serious adverse events (>1) were reported in 1.7% UST and 2% placebo of patients.

This double-bind placebo controlled trial followed 615 patients with active PsA (≥5 swollen joint counts and ≥5 tender joint counts; c-reactive protein ≥0.3mg/dL) despite treatment with disease modifying anti-rheumatic drugs (DMARDs) and/or non-steroidal anti inflammatory drugs (NSAIDs). Patients were randomised to UST 45mg, 90mg or placebo at weeks zero, four and 12 weeks thereafter. At week 16, patients with <5% improvement in tender joint counts and swollen joint counts entered blinded early escape (PBO to UST 45mg, UST 45mg to UST 90mg, UST 90mg to UST 90mg). Stable concomitant methotrexate (MTX) use was permitted but not mandated. Nearly half of the patients studied used concomitant MTX at baseline but this did not alter the likelihood of benefit of UST.


Contact: Candice Debleu
European League Against Rheumatism

Related medicine news :

1. Personalizing biologic treatment to individual patients with rheuatoid arthritis is cost-effective
2. Patients taking certolizumab pegol are twice as likely to achievE ACR20 compared to placebo
3. Control of disease activity and biologic treatment increase life expectency in RA patients
4. Haematopoietic stem cell transplantation increases survival in systemic sclerosis patients
5. Financial Worries Add to Cancer Patients Burden
6. Caring for patients with fecal incontinence costs more than $4,000 per person each year
7. Pre-op Treatments Boost Survival for Esophageal Cancer Patients: Study
8. ASCO: Younger colon cancer patients have worse prognosis at diagnosis, yet better survival
9. Just do it! not good enough for cancer patients, UR researchers say
10. Skin transplant offers new hope for vitiligo patients
11. Nordic Walking a Winner for Heart Failure Patients, Study Says
Post Your Comments:
(Date:6/25/2016)... California (PRWEB) , ... June 25, 2016 , ... "With ... fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... customizable and all within Final Cut Pro X . Simply select a ProHand ...
(Date:6/25/2016)... ... , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department ... in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at ... Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 ...
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its ... Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding ... Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, we ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Bracket , a ... its next generation clinical outcomes platform, Bracket eCOA (SM) ... on June 26 – 30, 2016 in Philadelphia ... electronic Clinical Outcome Assessment product of its kind to fully ... Bracket eCOA 6.0 is a flexible platform for ...
(Date:6/23/2016)... Ill. and INDIANAPOLIS , ... students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is ... 2016 scholarship winners, announced today online at ... let type 1 diabetes stand in the way of ... has supported the Foundation,s scholarship program since 2012, and ...
(Date:6/23/2016)... -- Revolutionary technology includes multi-speaker listening to ... leaders in advanced audiology and hearing aid technology, has ... the world,s first internet connected hearing aid that opens ...      (Photo: ) , ... firsts,: , TwinLink™ - the first dual ...
Breaking Medicine Technology: